KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C - Trial NCT03995485
Access comprehensive clinical trial information for NCT03995485 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kawin Technology Share-holding Co., Ltd. and is currently Completed. The study focuses on Hepatitis C, Chronic. Target enrollment is 371 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kawin Technology Share-holding Co., Ltd.
Timeline & Enrollment
Phase 3
Jun 07, 2017
Mar 07, 2018
Primary Outcome
Sustained virologic response at 12 weeks after end of treatment (SVR12)
Summary
This study aimed to confirm efficacy and safety of KW-136, an investigational anti-hepatitis
 C virus (HCV) drug, combined with sofosbuvir for treatment of naive and experienced adults
 chronically infected with HCV. Three hundred and sixty (360) non-cirrhotic and cirrhotic
 subjects were medicated with KW-136 60 mg daily and sofosbuvir 400 mg daily. The treatment
 course lasted 12 successive weeks; thereafter all the study participants entered into a
 12-week treatment-free follow-up period and an additional 12-week extension treatment-free
 follow-up period.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03995485
Non-Device Trial